Holen Sie sich die Stockscreener-App
34.07
2.53%
0.84
Schlusskurs vom Vortag:
$33.23
Offen:
$33.17
24-Stunden-Volumen:
489.15K
Relative Volume:
0.71
Marktkapitalisierung:
$1.91B
Einnahmen:
$681.88M
Nettoeinkommen (Verlust:
$122.63M
KGV:
13.85
EPS:
2.46
Netto-Cashflow:
$220.18M
1W Leistung:
+2.57%
1M Leistung:
-2.27%
6M Leistung:
+12.85%
1J Leistung:
+19.54%
1-Tages-Spanne:
$32.90
$34.17
1-Wochen-Bereich:
$32.33
$34.17
52-Wochen-Spanne:
$28.14
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Vergleichen Sie HRMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HRMY | 34.07 | 1.91B | 681.88M | 122.63M | 220.18M | 2.46 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Pacer Advisors Inc. Decreases Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES - Lelezard
Harmony Biosciences to Present at Citi and Piper Sandler Healthcare Conferences | HRMY Stock News - StockTitan
Harmony Biosciences Reports Record Revenue and Plans Expansion in CNS Treatments - MSN
HRMY (Harmony Biosciences Holdings) GF Value Rank : 4 (As of Nov. 20, 2024) - GuruFocus.com
Principal Financial Group Inc. Sells 19,654 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Quest Partners LLC Acquires 20,689 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
First Week of July 2025 Options Trading For Harmony Biosciences Holdings (HRMY) - Nasdaq
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Drop in Short Interest - MarketBeat
14,396 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Purchased by CWA Asset Management Group LLC - MarketBeat
Harmony Biosciences’ Common Stock Offering - Global Legal Chronicle
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points (NASDAQ:HRMY) - Seeking Alpha
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Harmony Biosciences director Antonio Gracias sells $139m in stock - Investing.com India
Marshman Fund Trust II sells $139.39 million in Harmony Biosciences stock - Investing.com
Harmony Biosciences director Antonio Gracias sells $139m in stock By Investing.com - Investing.com UK
AlphaCentric Advisors LLC Has $3.88 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings - Yahoo Canada Finance
Top 5 US Stocks To Buy In November 2024 - Investing.com
HRMY vs. REGN: Which Stock Is the Better Value Option? - MSN
(HRMY) Trading Signals - Stock Traders Daily
Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? - Yahoo Finance
Harmony Bio, The No. 1 Biotech Stock, Surges On Its 'High Quality' Beat - MSN
Harmony Biosciences Holdings Prices of Public Offering of Common Stock - citybiz
Harmony Biosciences chief commercial officer sells $870,018 in stock - Investing.com India
Harmony Biosciences chief commercial officer sells $870,018 in stock By Investing.com - Investing.com Canada
Latham Advises Harmony Biosciences Holdings, Inc. in Public Offering of Common Stock by Selling Shareholders - Latham & Watkins LLP
HRMY Makes Notable Cross Below Critical Moving Average - Nasdaq
Harmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Estimate for HRMY Earnings - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2024 Earnings Call Transcript - Insider Monkey
Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next - Simply Wall St
Goldman Sachs maintains sell rating on HRMY stock with $28 target - Investing.com Canada
Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Hi - GuruFocus.com
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders - StockTitan
Harmony’s Wakix Surpasses $2B in Revenue, Data Shows Promise for IH Treatment - Sleep Review
Goldman Sachs maintains sell rating on HRMY stock with $28 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald Raises Harmony Biosciences (NASDAQ:HRMY) Price Target to $58.00 - MarketBeat
Harmony Biosciences' (HRMY) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
Harmony Biosciences: Strong Q3 and Future Growth - MSN
Harmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Shares Gap DownHere's Why - MarketBeat
Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt? - Simply Wall St
Harmony Biosciences stock hits 52-week high at $40.73 By Investing.com - Investing.com Australia
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com
Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ... - Investing.com Canada
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUA - GuruFocus.com
Harmony Biosciences initiates public stock offering by shareholders By Investing.com - Investing.com South Africa
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):